Immunocore (NASDAQ:IMCR) Hits New 1-Year Low – Here’s What Happened

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) hit a new 52-week low on Tuesday. The stock traded as low as $27.31 and last traded at $27.74, with a volume of 259,620 shares. The stock had previously closed at $28.88.

Analyst Ratings Changes

Several research firms have recently issued reports on IMCR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. HC Wainwright dropped their price target on shares of Immunocore from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday, November 10th. BTIG Research restated a “buy” rating on shares of Immunocore in a research report on Monday. JPMorgan Chase & Co. started coverage on shares of Immunocore in a report on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price for the company. Finally, Zacks Research cut shares of Immunocore from a “hold” rating to a “strong sell” rating in a research report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.86.

Get Our Latest Stock Report on Immunocore

Immunocore Trading Down 3.2%

The company has a debt-to-equity ratio of 0.94, a current ratio of 4.62 and a quick ratio of 4.59. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -40.97 and a beta of 0.82. The business’s 50 day simple moving average is $30.63 and its 200 day simple moving average is $31.56.

Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. The company had revenue of $102.22 million for the quarter, compared to analysts’ expectations of $152.09 million. Research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.20 EPS for the current year.

Hedge Funds Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Braidwell LP acquired a new position in Immunocore in the second quarter worth about $16,552,000. Janus Henderson Group PLC raised its stake in Immunocore by 30.9% during the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after buying an additional 140,308 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Immunocore during the second quarter valued at approximately $2,145,000. Stempoint Capital LP bought a new position in Immunocore during the 1st quarter worth approximately $1,916,000. Finally, Engineers Gate Manager LP lifted its holdings in Immunocore by 334.3% during the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after buying an additional 46,435 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Further Reading

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.